884331-12-8

Upstream product

• 884330-84-1 (R)-1-(3-Benzyloxy-phenyl)-2-bromo-ethanol 
• 100-39-0 benzyl bromide 
• 121-71-1 3-Hydroxyacetophenone 
• 34068-01-4 1-[3-(phenylmethoxy)phenyl]ethan-1-one 
• 776302-34-2 (R)-α-methyl-7-methanesulfonyloxytryptamine 
• 848072-79-7 [1-(3-benzyloxy-phenyl)-2-bromo-ethoxy]-tert-butyl-dimethyl-silane 

Downstream Products

• 848072-87-7 Methanesulfonic acid 3-{(R)-2-[(R)-2-(3-benzyloxy-phenyl)-2-hydroxy-ethylamino]-propyl}-1H-indol-7-yl ester 
• 884331-33-3 benzenesulfonic acid 3-(2-{tert-butoxycarbonyl-[2-(7-methanesulfonyloxy-1H-indol-3-yl)-1-methyl-ethyl]-amino}-1-hydroxy-ethyl)-phenyl ester 
• 884331-11-7 methanesulfonic acid 3-(2-{tert-butoxycarbonyl-[2-hydroxy-2-(3-hydroxy-phenyl)-ethyl]-amino}-propyl)-1H-indol-7-yl ester 

Relevant academic research and scientific papers

Tryptamine-based human β3-adrenergic receptor agonists. Part 3: Improved oral bioavailability via modification of the sulfonamide moiety

The continued SAR investigation of tryptamine-based human β3-adrenergic receptor (AR) agonists is reported. Prior efforts resulted in the identification of 2 as a potent β3-AR agonist. Further modification of the left side arylsulfonamide portion in 2 provided compounds with good cell permeability, which have potent agonistic activity for β3-AR. Cinnamylamine analog 16i exhibited an excellent agonistic profile in vitro and good oral bioavailability in rats.